Hot ‰ash (HF) is the most common phenomenon in climacteric symptoms which often develop concomitantly with a decrease in estrogen in postmenopausal women. The onset mechanism of the hot ‰ash is complicated and remains unclear. To date, some animal models of postmenopausal HF have been devised, but they are not fully available because of the di‹culty in producing them. It is thought that hyperactivity of the central a-adrenergic system with a decrease in estrogen participates in the onset of postmenopausal HF. Therefore, in the present study, we examined whether a HF model could be easily produced by administering yohimbine (YOH), a presynaptic a 2 -adrenoceptor antagonist which promotes norepinephrine release, to female rats. HF-like symptoms such as a rise in tail skin temperature and a fall in rectal temperature were shown in the rats who received YOH (3 mg/kg) subcutaneously seven days after the ovariectomy (OVX). Such symptoms following YOH administration were observed in sham rats as well, but were much more clearly noted in OVX rats. We next examined the eŠects of various drugs, which are clinically eŠective against postmenopausal HF, on HF-like symptoms in YOH-treated OVX rats: clonidine, a presynaptic a 2 -adrenoceptor agonist which inhibits norepinephrine release; b-estradiol as an estrogen; and Keishibukuryogan, a Kampo medicine. These drugs inhibited HF-like symptoms in YOH-treated OVX rats. These results suggest that the activity of the a-adrenergic system is enhanced with a decrease in estrogen in OVX rats whereby YOH causes HF-like symptoms more conspicuously than in sham rats. Therefore, it is thought that YOH-treated OVX rats will be a novel and simple model of postmenopausal HF.
Rats were anesthetized with ether inhalation and bilaterally ovariectomized (OVX) or sham-operated. Seven days postoperatively, yohimbine hydrochloride (YOH) was administered subcutaneously to the rats at a dose of 1 or 3 mg/kg and then tail skin temperature (TST) and rectal temperature (RT) were measured. Data are represented by the mean±S.E.M. of 5 (YOH 1 mg/kg) or 6 (YOH 3 mg/kg) animals. The statistical diŠerence was assessed using the Student's t-test: p ＜0.05,  p＜0.01, comparison between Sham and OVX group. Rats were anesthetized with ether inhalation and bilaterally ovariectomized (OVX) or sham-operated. Seven days postoperatively, yohimbine hydrochloride (YOH) was administered subcutaneously to the rats at a dose of 3 mg/kg and then tail skin temperature (TST) and rectal temperature (RT) were measured. b-Estradiol (E 2 ; 30 mg/kg) was administered subcutaneously for 7 days before YOH treatment. After the measurement of TST and RT, rats were sacriˆced, and then the uterus was removed and weighed. Data are represented by the mean±S.E.M. of 6 animals. The statistical diŠerence was assessed using the Tukey- Rats were anesthetized with ether inhalation and bilaterally ovariectomized (OVX) or sham-operated. Seven days postoperatively, yohimbine hydrochloride (YOH) was administered subcutaneously to the rats at a dose of 3 mg/kg and then tail skin temperature (TST) and rectal temperature (RT) were measured. Keishibukuryogan (KBG; 1000 mg/kg) or b-estradiol (E 2 ; 30 mg/kg) was administered orally or subcutaneously, respectively, for 7 days before YOH treatment. After the measurement of TST and RT, rats were sacriˆced, and then the uterus was removed and weighed. Data are represented by the mean±S.E.M. of 7 animals. The statistical diŠerence was assessed using the Tukey- 
